Primary nocturnal enuresis. Nonorganic enuresis
Conditions
Interventions
Intervention 1: In two-drug regimen group: Tolterodin 2 mg/day orally plus nasal Desmopressin 1 puff/night for 4 weeks. Intervention 2: In one-drug regimen group: nasal Desmopressin 1 puff/night and
Treatment - Drugs
In two-drug regimen group: Tolterodin 2 mg/day orally plus nasal Desmopressin 1 puff/night for 4 weeks
In one-drug regimen group: nasal Desmopressin 1 puff/night and placebo with the same shape, size and color of the Tolterodin once per night orally for 4 weeks
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 16 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: (having primary nocturnal enuresis; not having secondary nocturnal risk factors such as urinary tract infection, constipation, Diabetes Mellitus, Diabetes Insipidus, obstruction of the urinary tract, neurogenic bladder and positive history of seizure; to be between 5 to 16 years old) Exclusion criteria: (having abnormal sonographic or urine analysis results; occurrence of side effects or missing the intake of more than two doses of the prescribed drugs)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of nocturnal urination in a week. Timepoint: weekly for four weeks. Method of measurement: Using a questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of side effects. Timepoint: Weekly for four weeks. Method of measurement: Physical examination by a specialist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAdorreza Otofat
Tabriz University of Medical Sciences
Outcome results
None listed